Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Neil HerskowitzDirector | Avenue TherapeuticsATXI | Open-market sale | 24/12/02 | 24/12/03 | 23 sh | $2.00 | $46 | −19.2% |
Jay D. KranzlerDirector | Avenue TherapeuticsATXI | Open-market sale | 24/11/05 | 24/11/07 | 61 sh | $2.24 | $136.64 | −9.8% |
Avenue TherapeuticsATXI | Open-market buy | 24/09/27–24/09/30 | 24/10/01 | 500 sh2 trades | $2.50avg. | $1,249.7 | +416.7% | |
Avenue TherapeuticsATXI | Open-market sale | 23/12/11 | 23/12/13 | 617,000 sh6 trades | $0.14avg. | $86,560 | No record | |
Lindsay A. Md RosenwaldDirector | Avenue TherapeuticsATXI | Open-market buy | 23/09/08 | 23/09/12 | 348,675 sh | $0.72 | $251,046 | +6178.9% |
Fortress Biotech10% Owner | Avenue TherapeuticsATXI | Open-market buy | 23/09/08 | 23/09/12 | 418,410 sh | $0.72 | $301,255.2 | +68.1% |
